(Reuters) - AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023.
AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in 2023
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться